Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review

Journal of Infection and Public Health

Volumn 11, Issue 1, 2018, Pages 9-17

  Mustafa, Sabeena ^a   Balkhy, Hanan ^a   Gabere, Musa N ^a  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Antimicrobial peptides; Convalescent plasma; Interferon; Intravenous immunoglobin; MERS CoV; Peptide therapeutics; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; NONSTRUCTURAL PROTEIN; PEPTIDE; POLYCLONAL ANTIBODY; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; VIRAL PROTEIN; ANTIMICROBIAL CATIONIC PEPTIDE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BLOOD; CONVALESCENCE PLASMA THERAPY; CORONAVIRIDAE; DRUG MECHANISM; DRUG REPOSITIONING; HUMAN; MIDDLE EAST RESPIRATORY SYNDROME; NONHUMAN; PLASMA; PRIORITY JOURNAL; REVIEW; VIRUS ASSEMBLY; VIRUS ENTRY; VIRUS RELEASE; VIRUS REPLICATION; WHOLE BLOOD THERAPY; CLINICAL TRIAL (TOPIC); CORONAVIRUS INFECTION;

ANTIMICROBIAL CATIONIC PEPTIDES; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; CORONAVIRUS INFECTIONS; DRUG REPOSITIONING; HUMANS;

EID: 85028465604     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2017.08.009     Document Type: Review

References (109)

1. Petersen, E., Hui, D.S., Perlman, S., Zumla, A., Middle East Respiratory Syndrome – advancing the public health and research agenda on MERS – lessons from the South Korea outbreak. Int J Infect Dis 36 (2015), 54–55.
2. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D.M.E., Fouchier, R.A.M., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:19 (2012), 1814–1820.
3. Assiri, A., McGeer, A., Perl, T.M., Price, C.S., Al Rabeeah, A.A., Cummings, D.A.T., et al. Hospital outbreak of Middle East Respiratory Syndrome Coronavirus. N Engl J Med 369:5 (2013), 407–416.
4. Liu, Q., Xia, S., Sun, Z., Wang, Q., Du, L., Lu, L., et al. Testing of Middle East Respiratory Syndrome Coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother 59:1 (2015), 742–744.
5. Chan, R.W.Y., Chan, M.C.W., Agnihothram, S., Chan, L.L.Y., Kuok, D.I.T., Fong, J.H.M., et al. Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol 87:12 (2013), 6604–6614.
6. Josset, L., Menachery, V.D., Gralinski, L.E., Agnihothram, S., Sova, P., Carter, V.S., et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio 4:3 (2013), e00165–13.
7. Zumla, A., Hui, D.S., Perlman, S., Middle East Respiratory Syndrome. Lancet 386:9997 (2015), 995–1007.
8. Chowell, G., Blumberg, S., Simonsen, L., Miller, M.A., Viboud, C., Synthesizing data and models for the spread of MERS-CoV, 2013: key role of index cases and hospital transmission. Epidemics 0 (2014), 40–51.
9. Ge, X.-Y., Li, J.-L., Yang, X.-L., Chmura, A.A., Zhu, G., Epstein, J.H., et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503:7477 (2013), 535–538.
10. Coleman, C.M., Frieman, M.B., Emergence of the Middle East Respiratory Syndrome coronavirus. PLoS Pathog, 9(9), 2013, e1003595.
11. Xia, S., Liu, Q., Wang, Q., Sun, Z., Su, S., Du, L., et al. Middle East Respiratory Syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res 194 (2014), 200–210.
12. Surya, W., Li, Y., Verdià-Bàguena, C., Aguilella, V.M., Torres, J., MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels. Virus Res 201 (2015), 61–66.
13. Surya, W., Samsó M., Torres, J., Structural and functional aspects of viroporins in human respiratory viruses: respiratory syncytial virus and coronaviruses. 2013.
14. Liu, J., Sun, Y., Qi, J., Chu, F., Wu, H., Gao, F., et al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J Infect Dis 202:8 (2010), 1171–1180.
15. de Haan, C.A.M., Rottier, P.J.M., Molecular interactions in the assembly of coronaviruses. Advances in virus research, 2005, Academic Press, 165–230.
16. Cho, C.-C., Lin, M.-H., Chuang, C.-Y., Hsu, C.-H., Macro domain from Middle East Respiratory Syndrome Coronavirus (MERS-CoV) is an efficient ADP-ribose binding module: crystak structure and biochemcall studies. J Biol Chem 291:10 (2016), 4894–4902.
17. Zumla, A., Chan, J.F.W., Azhar, E.I., Hui, D.S.C., Yuen, K.-Y., Coronaviruses drug discovery and therapeutic options. Nat Rev Drug Discov 15:5 (2016), 327–347.
18. Durai, P., Batool, M., Shah, M., Choi, S., Middle East Respiratory Syndrome Coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control. Exp Mol Med, 47, 2015, e181.
19. Aouadi, W., Blanjoie, A., Vasseur, J.-J., Debart, F., Canard, B., Decroly, E., Binding of the methyl donor SAM to MERS-CoV 2′-O-methyltransferase nsp16 promotes the recruitment of the allosteric activator nsp10. J Virol, 2016.
20. St. John, S.E., Mesecar, A.D., Design, synthesis, and development of broad spectrum coronaviral 3C-like protease inhibitors to target emerging human pathogens: a phylochemical approach. FASEB J, 30(1 Suppl), 2016 842.4.
21. Tomar, S., Johnston, M.L., St John, S.E., Osswald, H.L., Nyalapatla, P.R., Paul, L.N., et al. Ligand-induced dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CL(pro)): implications for nsp5 regulation and the development of antivirals. J Biol Chem 290:32 (2015), 19403–19422.
22. Wang, F., Chen, C., Tan, W., Yang, K., Yang, H., Structure of main protease from human coronavirus NL63: insights for wide spectrum anti-coronavirus drug design, 6, 2016, 22677.
23. Dassault Systèmes BIOVIA. Discovery studio modeling environment. 2016 (Release 2017, San Diego: Dassault Systèmes, 2016).
24. Adedeji, A.O., Sarafianos, S.G., Antiviral drugs specific for coronaviruses in preclinical development. Curr Opin Virol 0 (2014), 45–53.
25. de Wilde, A.H., Jochmans, D., Posthuma, C.C., Zevenhoven-Dobbe, J.C., van Nieuwkoop, S., Bestebroer, T.M., et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East Respiratory Syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58:8 (2014), 4875–4884.
26. Dyall, J., Coleman, C.M., Hart, B.J., Venkataraman, T., Holbrook, M.R., Kindrachuk, J., et al. Repurposing of clinically developed drugs for treatment of Middle East Respiratory Syndrome Coronavirus infection. Antimicrob Agents Chemother 58:8 (2014), 4885–4893.
27. Cao, J., Forrest, J.C., Zhang, X., A screen of the NIH clinical collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Res 114 (2015), 1–10.
28. Falzarano, D., de Wit, E., Martellaro, C., Callison, J., Munster, V.J., Feldmann, H., Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep, 3, 2013, 1686.
29. Booth, C.M., Matukas, L.M., Tomlinson, G.A., et al. Clinical features and short-term outcomes of 144 patients with sars in the greater toronto area. JAMA 289:21 (2003), 2801–2809.
30. Rossignol, J.-F., Nitazoxanide a new drug candidate for the treatment of Middle East Respiratory Syndrome Coronavirus. J Infect Public Health 9:3 (2016), 227–230.
31. Lin, S.-C., Ho, C.-T., Chuo, W.-H., Li, S., Wang, T.T., Lin, C.-C., Effective inhibition of MERS-CoV infection by resveratrol. BMC Infect Dis, 17, 2017, 144.
32. de Wilde, A.H., Falzarano, D., Zevenhoven-Dobbe, J.C., Beugeling, C., Fett, C., Martellaro, C., et al. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model. Virus Res 228 (2017), 7–13.
33. JF-W, Chan, Yao, Y., Yeung, M.-L., Deng, W., Bao, L., Jia, L., et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212:12 (2015), 1904–1913.
34. Falzarano, D., de Wit, E., Rasmussen, A.L., Feldmann, F., Okumura, A., Scott, D.P., et al. Interferon-α2b and ribavirin treatment improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 19:10 (2013), 1313–1317.
35. Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., et al. Ribavirin and interferon alfa-2a for severe Middle East Respiratory Syndrome Coronavirus infection: a retrospective cohort study. Lancet Infect Dis 14:11 (2014), 1090–1095.
36. Kim, U., Won, E., Kee, S., Jung, S., Jang, H., Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East Respiratory Syndrome. Antiviral Ther 21:5 (2016), 455–459.
37. Tawalah, H.A., Al-Qabandi, M., Sadiq, M., Chehadeh, C., Al-Hujailan, G., Al-Qaseer, M., The most effective therapeutic regimen for patients with severe Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. J Infect Dis Ther, 3(4), 2015.
38. Al-Tawfiq, J.A., Momattin, H., Dib, J., Memish, Z.A., Ribavirin and interferon therapy in patients infected with the Middle East Respiratory Syndrome Coronavirus: an observational study. Int J Infect Dis 20 (2014), 42–46.
39. Khalid, M., Al Rabiah, F., Khan, B., Al Mobeireek, A., Butt, T.S., Al Mutairy, E., Ribavirin and interferon-α2b as primary and preventive treatment for Middle East Respiratory Syndrome Coronavirus: a preliminary report of two cases. Antiviral Ther 20 (2015), 87–91.
40. Shalhoub, S., Farahat, F., Al-Jiffri, A., Simhairi, R., Shamma, O., Siddiqi, N., et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East Respiratory Syndrome Coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 70:7 (2015), 2129–2132.
41. Chan, J.F.W., Chan, K.-H., Kao, R.Y.T., To, K.K.W., Zheng, B.-J., Li, C.P.Y., et al. Broad-spectrum antivirals for the emerging Middle East Respiratory Syndrome Coronavirus. J Infect 67:6 (2013), 606–616.
42. Arabi, Y., Balkhy, H., Hajeer, A.H., Bouchama, A., Hayden, F.G., Al-Omari, A., et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East Respiratory Syndrome Coronavirus infection: a study protocol. SpringerPlus, 4(709), 2015.
43. Marano, G., Vaglio, S., Pupella, S., Facco, G., Catalano, L., Liumbruno, G.M., et al. Convalescent plasma: new evidence for an old therapeutic tool?. Blood Transfus 14:2 (2016), 152–157.
44. Chong, Y.P., Song, J.Y., Seo, Y.B., Choi, J.-P., Shin, H.-S., Rapid Response T. Antiviral Treatment Guidelines for Middle East Respiratory Syndrome. Infect Chemother 47:3 (2015), 212–222.
45. Hartung, H.P., Mouthon, L., Ahmed, R., Jordan, S., Laupland, K.B., Jolles, S., Clinical applications of intravenous immunoglobulins (IVIg) – beyond immunodeficiencies and neurology. Clin Exp Immunol 158:Suppl. 1 (2009), 23–33.
46. Jolles, S., Sewell, W.A.C., Misbah, S.A., Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142:1 (2005), 1–11.
47. Luke, T., Wu, H., Zhao, J., Channappanavar, R., Coleman, C.M., Jiao, J.-A., et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci Trans Med, 8(326), 2016 326ra21-ra21.
48. Sakamoto, S., Tanaka, H., Morimoto, S., Towards the prophylactic and therapeutic use of human neutralizing monoclonal antibodies for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Ann Trans Med, 3(3), 2015, 35.
49. Corti, D., Passini, N., Lanzavecchia, A., Zambon, M., Rapid generation of a human monoclonal antibody to combat Middle East Respiratory Syndrome. J Infect Public Health 9:3 (2016), 231–235.
50. Corti, D., Zhao, J., Pedotti, M., Simonelli, L., Agnihothram, S., Fett, C., et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci 112:33 (2015), 10473–10478.
51. Tang, X.-C., Agnihothram, S.S., Jiao, Y., Stanhope, J., Graham, R.L., Peterson, E.C., et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci 111:19 (2014), E2018–E2026.
52. Jiang, L., Wang, N., Zuo, T., Shi, X., Vincent Poon, K.-M., Wu, Y., et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Trans Med, 6(234), 2014, 234ra59.
53. Pascal, K.E., Coleman, C.M., Mujica, A.O., Kamat, V., Badithe, A., Fairhurst, J., et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci 112:28 (2015), 8738–8743.
54. Tang, X.-C., Agnihothram, S.S., Jiao, Y., Stanhope, J., Graham, R.L., Peterson, E.C., et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci U S A 111:19 (2014), E2018–E2026.
55. Johnson, R.F., Bagci, U., Keith, L., Tang, X., Mollura, D.J., Zeitlin, L., et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology 490 (2016), 49–58.
56. Agrawal, A.S., Ying, T., Tao, X., Garron, T., Algaissi, A., Wang, Y., et al. Passive transfer of a germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal Middle East Respiratory Syndrome Coronavirus infection. Sci Rep, 6, 2016, 31629.
57. Ying, T., Du, L., Ju, T.W., Prabakaran, P., Lau, C.C.Y., Lu, L., et al. Exceptionally potent neutralization of Middle East Respiratory Syndrome Coronavirus by human monoclonal antibodies. J Virol 88:14 (2014), 7796–7805.
58. Ying, T., Prabakaran, P., Du, L., Shi, W., Feng, Y., Wang, Y., et al. Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat Commun, 6, 2015, 8223.
59. Qiu, H., Sun, S., Xiao, H., Feng, J., Guo, Y., Tai, W., et al. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East Respiratory Syndrome (MERS)-coronavirus infection. Antivir Res 132 (2016), 141–148.
60. Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J., et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res 25:11 (2015), 1237–1249.
61. Nelson, P.N., Reynolds, G.M., Waldron, E.E., Ward, E., Giannopoulos, K., Murray, P.G., Demystified monoclonal antibodies. Mol Pathol 53:3 (2000), 111–117.
62. Shirato, K., Kawase, M., Matsuyama, S., Middle East Respiratory Syndrome Coronavirus infection mediated by the Transmembrane Serine Protease TMPRSS2. J Virol 87:23 (2013), 12552–12561.
63. Gierer, S., Bertram, S., Kaup, F., Wrensch, F., Heurich, A., Krämer-Kühl, A., et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 87:10 (2013), 5502–5511.
64. Millet, J.K., Whittaker, G.R., Host cell entry of Middle East Respiratory Syndrome Coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci U S A 111:42 (2014), 15214–15219.
65. Coleman, C.M., Sisk, J.M., Mingo, R.M., Nelson, E.A., White, J.M., Frieman, M.B., Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East Respiratory Syndrome Coronavirus fusion. J Virol 90:19 (2016), 8924–8933.
66. Wrensch, F., Winkler, M., Pöhlmann, S., IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms. Viruses 6:9 (2014), 3683–3698.
67. Luo, Y., Ou, R., Ling, Y., Qin, T., The therapeutic effect of high flow nasal cannula oxygen therapy for the first imported case of Middle East Respiratory Syndrome to China. Chin Crit Care Med 10 (2015), 841–844.
68. Lundin, A., Dijkman, R., Bergström, T., Kann, N., Adamiak, B., Hannoun, C., et al. Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East Respiratory Syndrome virus. PLoS Pathog, 10(5), 2014, e1004166.
69. Peters, H.L., Jochmans, D., de Wilde, A.H., Posthuma, C.C., Snijder, E.J., Neyts, J., et al. Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. Bioorg Med Chem Lett 25:15 (2015), 2923–2926.
70. Adedeji, A.O., Singh, K., Kassim, A., Coleman, C.M., Elliott, R., Weiss, S.R., et al. Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East Respiratory Syndrome Coronaviruses. Antimicrob Agents Chemother 58:8 (2014), 4894–4898.
71. de Wilde, A.H., Raj, V.S., Oudshoorn, D., Bestebroer, T.M., van Nieuwkoop, S., Limpens, R.W.A.L., et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J Gen Virol 94:Pt 8 (2013), 1749–1760.
72. Fosgerau, K., Hoffmann, T., Peptide therapeutics: current status and future directions. Drug Discov Today 20:1 (2015), 122–128.
73. Kaspar, A.A., Reichert, J.M., Future directions for peptide therapeutics development. Drug Discov Today 18:17-18 (2013), 807–817.
74. Bruno, B.J., Miller, G.D., Lim, C.S., Basics and recent advances in peptide and protein drug delivery. Ther Deliv 4:11 (2013), 1443–1467.
75. Ali, M.M., Karasneh, G.A., Jarding, M.J., Tiwari, V., Shukla, D., A 3-O-sulfated heparan sulfate binding peptide preferentially targets herpes simplex virus 2-infected cells. J Virol 86:12 (2012), 6434–6443.
76. Tincho, M.B., Gabere, M.N., Pretorius, A., In silico identification and molecular validation of putative antimicrobial peptides for HIV therapy. J AIDS Clin Res, 7(606), 2016.
77. Melnik, L.I., Garry, R.F., Morris, C.A., Peptide inhibition of human cytomegalovirus infection. Virol J, 8(1), 2011, 76.
78. Koehler, J.W., Smith, J.M., Ripoll, D.R., Spik, K.W., Taylor, S.L., Badger, C.V., et al. A fusion-inhibiting peptide against rift valley fever virus inhibits multiple, diverse viruses. PLoS Negl Trop Dis, 7(9), 2013, e2430.
79. Vigant, F., Santos, N.C., Lee, B., Broad-spectrum antivirals against viral fusion. Nat Rev Micro 13:7 (2015), 426–437.
80. Chen, Y., Cao, L., Zhong, M., Zhang, Y., Han, C., Li, Q., et al. Anti-HIV-1 activity of a new scorpion venom peptide derivative Kn2-7. PLoS One, 7(4), 2012, e34947.
81. Albericio, F., Kruger, H.G., Therapeutic peptides. Future Med Chem 4:12 (2012), 1527–1531.
82. Qureshi, A., Thakur, N., Tandon, H., Kumar, M., AVPdb: a database of experimentally validated antiviral peptides targeting medically important viruses. Nucleic Acids Res 42:Database issue (2014), D1147–D1153.
83. Fjell, C.D., Hancock, R.E.W., Cherkasov, A., AMPer: a database and an automated discovery tool for antimicrobial peptides. Bioinformatics 23:9 (2007), 1148–1155.
84. Fjell, C.D., Hiss, J.A., Hancock, R.E.W., Schneider, G., Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 11:1 (2012), 37–51.
85. Ganz, T., Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 3:9 (2003), 710–720.
86. Wang, Z., Wang, G., APD: the antimicrobial peptide database. Nucleic Acids Res 32:Database issue (2004), D590–D592.
87. Jenssen, H., Hamill, P., Hancock, R.E.W., Peptide antimicrobial agents. Clin Microbiol Rev 19:3 (2006), 491–511.
88. Harder, J., Schröder, J.M., Antimicrobial peptides role in human health and disease. 2015, Springer International Publishing.
89. Gallagher, T.M., Buchmeier, M.J., Coronavirus spike proteins in viral entry and pathogenesis. Virology 279:2 (2001), 371–374.
90. Taguchi, F., The S2 subunit of the murine coronavirus spike protein is not involved in receptor binding. J Virol 69:11 (1995), 7260–7263.
91. Taguchi, F., Shimazaki, Y.K., Functional analysis of an epitope in the S2 subunit of the murine coronavirus spike protein: involvement in fusion activity. J Gen Virol 81:12 (2000), 2867–2871.
92. Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., Jiang, S., The spike protein of SARS-CoV: a target for vaccine and therapeutic development. Nat Rev Microbiol 7:3 (2009), 226–236.
93. Hilchie, A.L., Wuerth, K., Hancock, R.E.W., Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol 9:12 (2013), 761–768.
94. Lu, L., Liu, Q., Zhu, Y., Chan, K.-H., Qin, L., Li, Y., et al. Structure-based discovery of Middle East Respiratory Syndrome Coronavirus fusion inhibitor. Nat Commun, 5, 2014.
95. Shuwen, L., Shuguang, W., Shibo, J., HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Des 13:2 (2007), 143–162.
96. Sainz, B., Mossel, E.C., Gallaher, W.R., Wimley, W.C., Peters, C.J., Wilson, R.B., et al. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. Virus Res 120:1-2 (2006), 146–155.
97. Rico-Mata, R., De Leon-Rodriguez, L.M., Avila, E.E., Effect of antimicrobial peptides derived from human cathelicidin LL-37 on Entamoeba histolytica trophozoites. Exp Parasitol 133:3 (2013), 300–306.
98. Wang, G., Natural antimicrobial peptides as promising anti-HIV candidates. Curr Topics Pept Protein Res 13 (2012), 93–110.
99. Zhao, H., Zhou, J., Zhang, K., Chu, H., Liu, D., Poon, V.K.-M., et al. A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep, 6, 2016, 22008.
100. de Wit, E., van Doremalen, N., Falzarano, D., Munster, V.J., SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Micro 14:8 (2016), 523–534.
101. Li, Q., Zhao, Z., Zhou, D., Chen, Y., Hong, W., Cao, L., et al. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides 32:7 (2011), 1518–1525.
102. Ke, M., Chen, Y., Wu, A., Sun, Y., Su, C., Wu, H., et al. Short peptides derived from the interaction domain of SARS coronavirus nonstructural protein nsp10 can suppress the 2′-O-methyltransferase activity of nsp10/nsp16 complex. Virus Res 167:2 (2012), 322–328.
103. Fehr, A.R., Perlman, S., Coronaviruses an overview of their replication and pathogenesis. Methods Mol Biol (Clifton, NJ) 1282 (2015), 1–23.
104. Gao, J., Lu, G., Qi, J., Li, Y., Wu, Y., Deng, Y., et al. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S Protein of Middle East Respiratory Syndrome Coronavirus. J Virol 87:24 (2013), 13134–13140.
105. Channappanavar, R., Lu, L., Xia, S., Du, L., Meyerholz, D.K., Perlman, S., et al. Protective effect of intranasal regimens containing peptidic Middle East Respiratory Syndrome Coronavirus fusion inhibitor against MERS-CoV Infection. J Infect Dis 212:12 (2015), 1894–1903.
106. Wang, G., Li, X., Wang, Z., APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res 44:Database issue (2016), D1087–D1093.
107. Ren, X., Liu, B., Yin, J., Zhang, H., Li, G., Phage displayed peptides recognizing porcine aminopeptidase N inhibit transmissible gastroenteritis coronavirus infection in vitro. Virology 410:2 (2011), 299–306.
108. Struck, A.-W., Axmann, M., Pfefferle, S., Drosten, C., Meyer, B., A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2. Antivir Res 94:3 (2012), 288–296.
109. Lu, W., Wu, X.-D., Shi, M.D., Yang, R.F., He, Y.Y., Bian, C., et al. Synthetic peptides derived from SARS coronavirus S protein with diagnostic and therapeutic potential. FEBS Lett 579:10 (2005), 2130–2136.